Medical Marijuana Laws: Are They Justified and Can They Work? | Research

The takeaway

A review found THC moderately effective for nausea, appetite loss, and pain, but argued the best therapeutic prospects lay in non-smoked delivery and synthetic cannabinoids rather than legalizing smoked cannabis.

Read this if you want to understand how different countries approached medical cannabis policy before widespread legalization.

THC moderately effective for nausea, appetite, and pain; dose titration difficult orally

What the researchers found

THC was moderately effective for nausea and vomiting, appetite loss, and acute and chronic pain. Oral THC (dronabinol) and nabilone were registered in the US and UK but not widely used because patients found dose titration difficult. Several jurisdictions had attempted different policy approaches: US states legislated medical cannabis but faced federal opposition; the UK recommended prescription but governments rejected the recommendation; Canada allowed prosecution exemptions and was moving toward prescription access.

The authors argued that full legalization would violate international drug treaties and was electorally unpopular. They concluded the best prospects were non-smoked THC delivery methods and synthetic cannabinoids with fewer psychoactive effects. As an interim measure, they suggested prosecution exemptions for patients with specified conditions.

Why it matters

This review captured the medical cannabis policy landscape at a pivotal moment when multiple countries were experimenting with different regulatory frameworks. The analysis of why each approach succeeded or failed provided a comparative framework that policymakers continue to reference.

The numbers in context

Alberta MS prevalence: 217 per 100,000 (cited as among the highest in the world). Various policy approaches across US, UK, Australia, and Canada were compared.

How the study worked

This was a policy review examining the evidence for medical cannabis effectiveness alongside the various legislative and regulatory approaches being attempted internationally.

What this study cannot tell us

The review reflected the evidence and policy landscape of 2003, which has changed substantially. The authors' preference for synthetic cannabinoids over plant cannabis was not borne out by market dynamics. The analysis may have underestimated patient and voter support for medical cannabis.

How to read the evidence

This is a policy review combining evidence assessment with regulatory analysis, providing moderate-level evidence.

When this study was published

Published in 2003. Medical cannabis policies have changed dramatically since, with many jurisdictions legalizing both medical and recreational use.

The bigger picture

Many of the predictions and recommendations in this review have been overtaken by events. Medical cannabis programs expanded dramatically worldwide, smoked cannabis became the dominant form despite recommendations against it, and the distinction between medical and recreational use has blurred in many jurisdictions.

Questions still open

Why did patients and voters consistently favor plant cannabis over synthetic alternatives despite expert recommendations? Has the expansion of medical cannabis programs created the public health problems that critics predicted?

Common questions

Why were early medical cannabis pills not popular?

Oral THC (dronabinol) and nabilone were available but patients found it difficult to control the dose. Inhaled cannabis provided faster onset and easier dose adjustment, which is why patients consistently preferred it despite medical recommendations for oral forms.

Did the prosecution exemption approach work?

Several jurisdictions tried exempting patients from criminal prosecution rather than fully legalizing. This was an intermediate step that many countries used before eventually establishing formal medical cannabis programs.

Read the original research

Medical marijuana initiatives : are they justified? How successful are they likely to be?

CNS drugs, 17(10), 689-97

View on PubMed ↗

Citation

Hall, Wayne; Degenhardt, Louisa. (2003). Medical marijuana initiatives : are they justified? How successful are they likely to be?. CNS drugs, 17(10), 689-97.